Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MuBBzT2
- Development stage
- Preclinical
- Lead developer
- Wellington Zhaotai Therapies
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MuBBzT2 is a chimeric antigen receptor (CAR) T-cell therapy developed by Wellington Zhaotai, specifically designed to target Mucin 1 (MUC1) for the treatment of lung cancer. The CAR construct features a 4-1BB (CD137) co-stimulatory domain and a CD3-zeta signaling domain, a combination intended to enhance the metabolic fitness, persistence, and anti-tumor activity of the engineered T cells. MUC1 is a transmembrane glycoprotein that is frequently overexpressed and aberrantly glycosylated in various epithelial cancers, including non-small cell lung cancer, providing a tumor-associated antigen for targeted immunotherapy. MuBBzT2 is currently in the preclinical stage of development as part of Wellington Zhaotai's pipeline of next-generation cell therapies.
- Other names
- Wellington Zhaotai MUC1 CAR-T
02
Targets
CD247 (T-cell surface glycoprotein CD3 epsilon chain)MUC1 (Mucin-1 Antigen)TNFRSF9 (CD137 extracellular domain)
Beyond the preview
Go deeper on MuBBzT2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MuBBzT2.